The 2025 Endocrine Society annual conference just wrapped up and we’re featuring some of the exciting research presentations to come out of the event. The ENDO 2025 conference took place July 12 through July 15 in San Francisco, California. We previewed the event, back in June. 

With four days full of insightful sessions, networking events, and research presentations, it can feel overwhelming to try and see everything. For your convenience, we are spotlighting some of the abstracts presented at ENDO 2025 related to neuroendocrinology. 

Cell Type-specific Distribution and Signaling Function of Somatostatin (SST) Receptors (SSTRs) in the Anterior Pituitary
  • Description: Using qRT-PCR and single-cell RNA sequencing, the researchers identified a cell type-specific distribution of SSTRs in rat pituitary cells: SSTR1 and SSTR2 were found in thyrotrophs, SSTR3 in gonadotrophs and lactotrophs, and SSTR2, SSTR3, and SSTR5 in somatotrophs, while SSTR mRNA was not detected in corticotrophs and melanotrophs.
  • Result: The study found that the absence of SSTRs in corticotrophs and melanotrophs likely contributes to their increased excitability and readiness to respond to stress.
Immune Checkpoint Inhibitor (ICI) Hypophysitis Involving the Posterior Pituitary with AVP Deficiency Presenting with Diabetic Ketoacidosis
  • Description: Researchers presented a case of a patient with ICI induced hypophysitis with central hypothyroidism/adrenal insufficiency who developed diabetic ketoacidosis.
  • Result: The study demonstrated the various endocrine manifestations of immune checkpoint inhibitor therapy and challenges in their management when they occur simultaneously. Similarly, it suggests that Arginine Vasopressin deficiency may be a more common complication than previously believed, and should be suspected for patients on immune checkpoint inhibitor therapy.
Insulin Resistance in Prostate Cancer Patients on Androgen Deprivation Therapy
  • Description: The researchers hypothesized that patients with higher insulin resistance would have excess loss of muscle mass, physical function, worsening mitochondrial respiration and poor patient reported outcomes after six months of starting androgen deprivation therapy.
  • Result: Researchers found that in men with prostate cancer initiating androgen deprivation therapy, baseline insulin resistance measured by HOMA_IR predicted greater declines in muscle mass, body weight, physical performance and quality of life after 6 months of treatment. Six months of androgen deprivation therapy lead to increases in insulin resistance, fat mass, and appetite.
Role of the Gut Microbiome in Androgen Production and Prostate Cancer Treatment Resistance
  • Description: This study aims to identify bacterial species responsible for gut androgen biosynthesis, determine if circulating and fecal androgen levels in individuals with metastatic castration resistant prostate cancer correlate with treatment response using metagenomics and metabolomic studies, and determine the relationship between gut androgen production and prostate cancer treatment response using in vivo mouse models.
  • Result: Researchers found that the ability of the human gut microbiota to harbor androgen-synthesizing bacteria, which in turn can be an alternative source of androgens that could impact prostate cancer treatment responsiveness.
Transient Suppression of Pituitary Function Induced by Treatment with TNF-alfa Inhibitor- Hypophysitis or Impairment in Regulation of Calcium as Intracellular Mediator?
  • Description: A variety of immune-related adverse events have been described in patients under biologic treatment, specially immune checkpoints inhibitors.
  • Result: Central hypogonadism, and GH and prolactin secretion were transiently impaired during treatment with TNF-α inhibitors, reversible after Adalimumab replacement. The reduction in pituitary volume and gonadotropic, somatotropic and lactotropic axis may suggest hypophysitis, but TNF-α inhibitors can reduce intracellular Ca2+ and could interfere along the secretory pathway.

Click here for the full schedule of all the research presented at ENDO2025.    

Sign up for alerts and stay informed on the latest published guidelines and articles.

Copyright © 2025 Guideline Central, all rights reserved.